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Background
Modern genotyping platforms permit a systematic search for inherited components 
of complex diseases. We performed a joint analysis of two genomewide association 
studies of coronary artery disease.
Methods
We first identified chromosomal loci that were strongly associated with coronary ar-
tery disease in the Wellcome Trust Case Control Consortium (WTCCC) study (which 
involved 1926 case subjects with coronary artery disease and 2938 controls) and looked 
for replication in the German MI [Myocardial Infarction] Family Study (which involved 
875 case subjects with myocardial infarction and 1644 controls). Data on other single-
nucleotide polymorphisms (SNPs) that were significantly associated with coronary 
artery disease in either study (P<0.001) were then combined to identify additional loci 
with a high probability of true association. Genotyping in both studies was performed 
with the use of the GeneChip Human Mapping 500K Array Set (Affymetrix).
Results
Of thousands of chromosomal loci studied, the same locus had the strongest as-
sociation with coronary artery disease in both the WTCCC and the German studies: 
chromosome 9p21.3 (SNP, rs1333049) (P = 1.80×10−14 and P = 3.40×10−6, respectively). 
Overall, the WTCCC study revealed nine loci that were strongly associated with 
coronary artery disease (P<1.2×10−5 and less than a 50% chance of being falsely 
positive). In addition to chromosome 9p21.3, two of these loci were successfully 
replicated (adjusted P<0.05) in the German study: chromosome 6q25.1 (rs6922269) 
and chromosome 2q36.3 (rs2943634). The combined analysis of the two studies 
identified four additional loci significantly associated with coronary artery disease 
(P<1.3×10−6) and a high probability (>80%) of a true association: chromosomes 
1p13.3 (rs599839), 1q41 (rs17465637), 10q11.21 (rs501120), and 15q22.33 (rs17228212).
Conclusions
We identified several genetic loci that, individually and in aggregate, substantially 
affect the risk of development of coronary artery disease.
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Coronary artery disease and its main complication, myocardial infarction, are leading causes of death and disability 
worldwide.1 Lifestyle and environmental factors 
play an important role in their development.2 In 
addition, these complex diseases cluster in fami-
lies, suggesting a substantial genetic cause.3 De-
spite extensive exploration of many genes, strong 
evidence of a molecular genetic association with 
coronary artery disease or myocardial infarction 
remains to be obtained.
The recent development of high-density geno-
typing arrays provides unprecedented resolution 
for whole-genome assessment of variants associ-
ated with common diseases.4 Using the GeneChip 
Human Mapping 500K Array Set (Affymetrix), 
which simultaneously types approximately 500,000 
genetic variants, the Wellcome Trust Case Con-
trol Consortium (WTCCC) recently reported on an 
analysis of data from approximately 2000 people 
(and a shared set of 3000 controls) for each of 
seven complex diseases, including coronary artery 
disease.5 Several loci showed strong associations 
with coronary artery disease, but the large num-
ber of statistical tests poses the challenge of 
discriminating between true and false associa-
tions. By providing a detailed analysis of the 
WTCCC data in conjunction with data from an-
other large genomewide association study, the 
German MI [Myocardial Infarction] Family Study, 
we sought robust evidence for associations of 
genetic loci with the risk of coronary artery dis-
ease and myocardial infarction.
Me thods
Subjects
All participants in both studies were of white Eu-
ropean origin. Detailed descriptions of recruitment 
and ascertainment in both studies are given in the 
Supplementary Appendix, available with the full 
text of this article at www.nejm.org. Local ethics 
committees approved the study protocols, and all 
participants gave written informed consent.
WTCCC Study
The 1988 case subjects in the WTCCC study had 
a history of either myocardial infarction or coro-
nary revascularization before the age of 66 years, 
as well as a strong family history of coronary ar-
tery disease.6,7 Two independent control groups 
were studied: 1504 controls from the British 1958 
Birth Cohort and 1500 controls selected from a 
sample of blood donors recruited as part of the 
WTCCC project.5 
German MI Family Study
The 875 case subjects in the German MI Family 
Study were persons who had myocardial infarction 
before the age of 60 years and at least one first-
degree relative with premature coronary artery 
disease.8,9 The 1644 controls were selected from 
a well-characterized random sample of German 
residents, stratified according to sex and age.10
Genotyping
All analyses were performed with the use of the 
GeneChip Human Mapping 500K Array Set, in-
cluding a StyI and a NspI chip. Details on geno-
type-calling algorithms, quality criteria (at the 
level of both the individual and the SNP), and 
validation steps are described in the Supplemen-
tary Appendix. This left 377,857 SNPs in 1926 
case subjects and 2938 controls in the WTCCC 
study and 272,602 SNPs in 870 and 772 case sub-
jects for the StyI chip and the NspI chips, respec-
tively, and from 1644 controls for both chips in 
the German study.
Statistical Analysis
Before performing the genetic analyses, we exam-
ined the data from each cohort individually for 
population substructure and ascertained that such 
variation was negligible in both studies (see the 
Supplementary Appendix). We then undertook 
three types of genetic analysis. First, after identi-
fying the SNPs with the strongest associations 
with coronary artery disease in the WTCCC sam-
ple, we sought to replicate these loci in the Ger-
man study (primary analysis). Second, we com-
bined data on other SNPs for which there was 
evidence of an association in either study, to iden-
tify additional loci with a low probability of be-
ing falsely positive (combined analysis). Third, we 
examined the data from both studies for associa-
tions with coronary artery disease among SNPs 
in genes reported to be associated with this dis-
ease (candidate-gene analysis).
Primary Analysis
All autosomal SNPs that showed evidence of a 
significant association with coronary artery dis-
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ease in the WTCCC study (P<0.001 with use of the 
two-sided Cochran–Armitage trend test) were as-
sessed for the false-positive-report probability 
(FPRP).11 (The rationale for the FPRP calculations 
and the assumptions underlying them are given 
in the Supplementary Appendix.) A small FPRP 
suggests that the association of a SNP is unlikely 
to be a false positive result. A SNP with an FPRP 
of less than 0.5 (i.e., one for which the chance of 
a truly positive association was greater than 50%), 
as well as SNPs within 100 kb in either direction 
of this SNP, also with P values of less than 0.001, 
were considered to represent a single locus. For-
mal replication testing of such loci was then per-
formed in the German study with the use of the 
lead SNP (defined as the SNP with the lowest 
FPRP) for each locus and adjustment for multiple 
testing. A P value of less than 0.05 with use of the 
two-sided Cochran–Armitage trend test was con-
sidered to indicate statistical significance. Hap-
lotype analysis was carried out on replicated loci, 
as described in the Supplementary Appendix. 
The power for replication in the German study 
was estimated for each locus for an odds ratio for 
myocardial infarction of 1.25 per allele and an 
adjusted significance level of 0.05.
Combined Analysis
All SNPs that showed evidence of a significant 
association (P<0.001) with coronary artery dis-
ease in the WTCCC study or with myocardial in-
farction in the German study were combined to 
assess their combined FPRP. Pooled odds ratios 
for the risk allele and 95% confidence intervals 
were calculated within each stratum, according 
to the study.
Candidate-Gene Analysis
Candidate genes were identified as described in 
the Supplementary Appendix. On the GeneChip 
array, we distinguished between SNPs that were 
identical to those identified in previous studies 
as showing an association with coronary artery 
disease and SNPs that were in complete or near-
complete linkage disequilibrium with those iden-
tified in previous studies as showing an associa-
tion with coronary artery disease. We used either 
of two measures of linkage disequilibrium — an 
r2 value of 0.8 or more or a disequilibrium coef-
ficient (D′) of 0.9 or more — on the basis of data 
from the International HapMap Project.12
Population Attributable Fractions
Population attributable fractions were estimated 
in the German study with the use of the lead SNP 
from each of the three replicated loci. Adjust-
ments were made for age, sex, the interaction 
between age and sex, the Prospective Cardiovas-
cular Munster (PROCAM) study score, and the 
Framingham risk score. Further details are given 
in the Supplementary Appendix.
Data Access
The WTCCC data are accessible at www.wtccc.
org.uk/info/summary_stats.shtml. The German 
MI Family Study data are available to academic 
researchers in a Web-based database (www. 
cardiogenics.imbs-luebeck.de).
R esult s
Characteristics of The Participants
In both the WTCCC and the German studies, the 
case subjects were young (mean age at first event, 
approximately 50 years) and had a strong famil-
ial basis for their disease (Table 1).
Primary Analysis
The distribution of P values for the association of 
SNPs with coronary artery disease in the WTCCC 
study and with MI in the German Study, accord-
ing to chromosome, is shown in Figure 1. In the 
WTCCC study, 396 SNPs were significantly as-
sociated with coronary artery disease (P<0.001). 
Thirty of these SNPs clustering in nine chromo-
somal regions met the predefined criterion of an 
FPRP of less than 0.5 (Table 1 in the Supplemen-
tary Appendix). We tested these nine loci for a 
significant association with myocardial infarc-
tion in the German study. Three of the loci — 
chromosomes 9p21.3, 6q25.1, and 2q36.3 — had 
such an association, even after adjustment for 
multiple testing for nine loci (Table 2).
The locus on chromosome 9p21.3 showed the 
strongest signal in both the WTCCC and the 
German studies (P = 1.80×10−14 and P = 3.40×10−6, 
respectively) (Fig. 1 and Table 2). The combined 
P value for the association with coronary artery 
disease of the lead SNP in that locus, rs1333049, 
was 2.91×10−19, with the risk increased by 36% 
per copy of the C allele (95% confidence interval 
[CI], 27 to 46). Approximately 22% of the study 
participants were homozygous for this allele, with 
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an additional 50% carrying a single copy. In the 
WTCCC and German studies, a similar pattern 
of association with respect to direction and mag-
nitude of effect was found across a region of ap-
proximately 100 kb on 9p21.3 (Fig. 2). The 19 
SNPs showing an association within this region 
were in strong linkage disequilibrium. However, 
two blocks could be distinguished, with strong 
linkage disequilibrium within each block (aver-
age D′>0.90) and moderate linkage disequilibri-
um between blocks (average D′, approximately 
0.60) (Fig. 2). Three SNPs in block 1 (rs7044859, 
rs1292136, and rs7865618) and one SNP in block 
2 (rs1333049) were sufficient to tag the region. 
Haplotype analysis showed that the association 
was mainly due to two mutually exclusive haplo-
types for the four SNPs (TTGG and ACAC) (Sup-
plementary Appendix). In the WTCCC study, the 
odds ratio for coronary artery disease with the 
ACAC haplotype (frequency, 0.324 among con-
trols and 0.386 among case subjects), as compared 
with the TTGG haplotype (frequency, 0.333 among 
controls and 0.271 among case subjects), was 
1.48 (95% CI, 1.34 to 1.64) per copy of the hap-
lotype (P = 2.1×10−14). The results of haplotype 
analysis in the German study were similar (Sup-
plementary Appendix).
The lead SNP on chromosome 6q25.1 
(rs6922269, with a combined P value of 2.90×10−8 
for the association with coronary artery disease) 
is in the gene for methylenetetrahydrofolate de-
hydrogenase (NADP+-dependent) 1–like protein 
(MTHFD1L). All positive SNPs in the region are 
located in introns in the middle portion of the 
gene (Fig. 1A in the Supplementary Appendix). 
The risk allele (A) for rs6922269 has a prevalence 
of approximately 25%, with the risk increased 
by 23% per copy (95% CI, 15 to 33). Haplotype 
analysis showed that only the two haplotypes 
carrying the A allele were more frequent in case 
subjects than in controls, confirming the in-
creased odds ratio for coronary artery disease 
with the A allele in the single-locus analysis (Sup-
plementary Appendix).
The third replicated locus, on chromosome 
2q36.3 (rs2943634, with a combined P value of 
1.61×10−7 for the association with coronary artery 
disease) encompasses a region of 233 kb (Fig. 1B 
in the Supplementary Appendix). There is only 
one pseudogene (ENSG00000197218) located 
within this region. The risk allele (C) for rs2943634 
has a prevalence of approximately 65%, with the 
risk increased by 21% per copy (95% CI, 13 to 30). 
Haplotype analysis showed that the other asso-
ciations observed in the linkage-disequilibrium 
block around rs2943634 are due to linkage dis-
equilibrium with it (Supplementary Appendix).
The association of the loci on chromosomes 
9p21.3 and 6q25.1 with myocardial infarction in 
the German study was not affected by adjust-
ment for cardiovascular risk factors and scores. 
In contrast, the odds ratio for myocardial infarc-
tion at the locus on chromosome 2q36.3 was 
n engl j med 357;5 www.nejm.org august 2, 2007
Table 1. Baseline Characteristics of Case Subjects in the WTCCC Study  
and the German MI Family Study.*
Characteristic
WTCCC Study 
(N = 1926)
German Study 
(N = 875)
Sex — no. (%)
Male 1527 (79.3) 591 (67.5)
Female 399 (20.7) 284 (32.5)
Mean age at first event — yr
Men 49.4±7.7 49.0±7.4
Women 51.0±7.4 52.8±8.2
Mean age at recruitment — yr 60.1±8.1 58.1±8.7
First event — no. (%)
MI 1377 (71.5) 875 (100.0)
PCI 202 (10.5)
CABG 347 (18.0)
Family history of CAD — no. (%)†
Father affected 570 (29.6) 151 (17.3)
Mother affected 302 (15.7) 114 (13.0)
Both parents affected 186 (9.7) 49 (5.6)
Sibling affected 1464 (76.0) 789 (90.2)
Cardiovascular risk factor — no. (%)‡
Former or current smoker 1460 (75.8) 615 (70.3)
Diabetes mellitus 211 (11.0) 108 (12.3)
Hypertension 822 (42.7) 757 (86.5)
Hyperlipidemia 1542 (80.0) 666 (76.1)
Obesity (body-mass index >30) 448 (23.3) 197 (22.5)
Receipt of lipid-lowering drugs — no. (%) 1429 (74.2) 575 (65.7)
* Plus–minus values are means ±SD. Details on the characteristics of controls 
for each study are given in the Methods section and the Supplementary Appen-
dix. MI denotes myocardial infarction, PCI percutaneous coronary interven-
tion, CABG coronary-artery bypass grafting, and CAD coronary artery disease.
† Parental history of CAD was based on reported history; sibling history of CAD 
was validated by direct examination of records.
‡ Diabetes, hypertension, and hyperlipidemia were identified as risk factors on 
the basis of the meeting of diagnostic criteria or the receipt of treatment for 
these conditions. The body-mass index is the weight in kilograms divided by 
the square of the height in meters.
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reduced after such adjustment (Table 2). Further 
analysis showed that this locus was also signifi-
cantly related to the body-mass index (P = 0.004 
in an additive model), the presence or absence of 
hypertension (P = 0.04), and the level of low-den-
sity lipoprotein cholesterol (P = 0.03). The fully ad-
justed population attributable fractions for the 
three loci in the German study are shown in 
Table 2. The combined fraction for the three loci 
was 0.38 (95% CI, 0.13 to 0.55). The prediction 
of myocardial infarction on the basis of the 
Framingham risk score and the PROCAM study 
score was substantially improved by adding the 
predictive information of these three loci to the 
model (deviance, 191.48; P<1×10−10).
For the six loci with an FPRP of less than 0.5 
in the WTCCC study for which the associations 
were not replicated in the German study, the re-
sults of each of the two studies are shown in Table 
2 in the Supplementary Appendix. The power to 
replicate these loci ranged from 43 to 80%.
Combined Analysis
The combined analysis of all SNPs identified four 
additional loci with a high likelihood of associa-
tion with coronary artery disease (FPRP <0.2) (Ta-
n engl j med 357;5 www.nejm.org august 2, 2007
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Figure 1. Signal-Intensity Plots Showing the Association of Single-Nucleotide Polymorphisms (SNPs) with Coronary 
Artery Disease or Myocardial Infarction in the Genomewide Association Analysis.
The −log P values are for the association of each SNP with coronary artery disease or myocardial infarction, from two-
sided Cochran–Armitage tests for trend. Only SNPs of sufficient quality (see the Supplementary Appendix) are shown. 
The signal-intensity plots of all SNPs with significant associations (P<0.001) were visually inspected by two indepen-
dent reviewers in each study to rule out possible artifactual results due to miscalling of genotypes (see Supplementary 
Appendix). Within each chromosome shown on the x axis, the data are plotted from the p-ter end. The y-axis scale for 
associations in the WTCCC study (Panel A) differs from the scale for the German MI Family Study (Panel B).
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ble 3, and Table 3 in the Supplementary Appen-
dix). The locus on chromosome 1p13.3 involves 
the PSRC1 gene, which encodes a proline-rich 
protein (Fig. 1C in the Supplementary Appendix). 
The other region of chromosome 1 (1q41) maps 
to the melanoma inhibitory activity 3 (MIA3) 
gene (also known as ARNT or TANGO) (Fig. 1D in 
the Supplementary Appendix). The SNPs associ-
ated with chromosome 10q11.21 cluster in a re-
gion 100 kb downstream of the CXCL12 gene 
(also known as the gene for stromal-cell–derived 
factor 1 precursor) (Fig. 1E in the Supplementary 
Appendix). Finally, the SNP on chromosome 
15q22.33 is an intronic SNP in the SMAD3 gene 
(Fig. 1F in the Supplementary Appendix). SMAD3 
is a transcriptional modulator activated by trans-
forming growth factor β (TGF-β) and activin 
type 1 receptor kinase.
Subphenotype and Subgroup Analysis
In the WTCCC study, approximately 30% of sub-
jects had confirmed evidence of coronary artery 
disease but had not had a myocardial infarction 
at the time of recruitment (Table 1). When sub-
jects with coronary artery disease only and those 
with coronary artery disease and myocardial in-
farction were analyzed individually, the odds ra-
tios for both phenotypes across all seven chro-
mosomal regions remained significant (Table 4 
in the Supplementary Appendix). For the chromo-
some 15 locus, the effect size was significantly 
greater (P = 0.004) in the subgroup of patients 
with coronary artery disease only than in the sub-
group with coronary artery disease and myocar-
dial infarction. Analysis according to sex in the 
two studies combined showed that all seven loci 
affected the risk of coronary artery disease to a 
similar extent in women and in men (Table 5 in 
the Supplementary Appendix).
Candidate-Gene Analysis
From a literature search, we identified 142 SNPs, 
in 91 candidate genes, that had been reported to 
be associated with coronary artery disease or 
myocardial infarction. Only 13 of these SNPs are 
represented on the GeneChip array. For 36 genes, 
n engl j med 357;5 www.nejm.org august 2, 2007
Table 2. Loci from the WTCCC Study with Significant Associations with Coronary Artery Disease That Were Replicated in the German MI 
Family Study.*
Chromosome Lead SNP
Minor Allele 
in Controls
Risk  
Allele Data Frequency of Minor Allele
Odds Ratio  
for Risk Allele  
(95% CI)
Population  
Attributable 
Fraction P Value
Case 
Subjects Controls
2 rs2943634 A C WTCCC 0.30 0.34 1.22 (1.11–1.33) 1.19×10−5
German 0.32 0.37 1.20 (1.06–1.35) 0.004
Adjusted 
German
1.08 (0.90–1.31) 0.10 0.03
6 rs6922269 A A WTCCC 0.29 0.25 1.23 (1.13–1.35) 6.33×10−6
German 0.30 0.26 1.24 (1.09–1.41) 0.001
Adjusted 
German
1.23 (1.01–1.50) 0.11 0.009
9 rs1333049 C C WTCCC 0.55 0.47 1.37 (1.26–1.48) 1.80×10−14
German 0.54 0.48 1.33 (1.18–1.51) 6.80×10−6
Adjusted 
German
1.28 (1.07–1.53) 0.22 6.12×10−5
* For each SNP, the odds ratios (with 95% confidence intervals) and P values given for the WTCCC and German data represent the risk of 
coronary artery disease associated with each copy of the risk allele and are based on the Cochran–Armitage test for trend, without adjust-
ment for covariates. The odds ratios and population attributable fractions for the adjusted German data are based on multivariate analyses 
with inclusion of all three lead SNPs and with adjustment for age, sex, the interaction between age and sex, the PROCAM study score, and 
the Framingham risk score. The P values for the adjusted German data were corrected for multiple testing (i.e., the testing of a total of nine  
loci for association with coronary artery disease) but were not adjusted for covariates. The location of the SNPs and details of their loci are 
shown in Figure 2 and in Figures 1A and 1B in the Supplementary Appendix. Further details on the SNPs, including genotype frequencies in 
the two studies, are given in Tables 1 and 3 in the Supplementary Appendix.
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Figure 2. Association Signal for Coronary Artery Disease on Chromosome 9.
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All data are from the Genome Browser of the University of California, Santa Cruz (NCBI build 35). Red boxes repre-
sent recombination hot spots, as estimated from HapMap data (Phase II, release 21) (III). Disequilibrium coefficient 
values for SNPs genotyped in case subjects with coronary artery disease in the WTCCC study, generated with the 
use of Haploview software, are shown (IV). There wer  two distinct blocks (1 and 2) of SNPs with significant asso-
ciations. Disequilibrium coefficients for all SNPs from HapMap CEU data (from persons of Northern and Western 
European ancestry) across chromosome 9, generated with the use of Haploview software, are shown (V). In IV and 
V, the strength of the linkage disequilibrium between SNPs increases from white to blue to red (white: disequilibri-
um coefficient <1 and LOD score <2; blue: disequilibrium coefficient = 1 and LOD score <2; pink or light red: dis-
equilibrium coefficient <1 and LOD score ≥2; and bright red: disequilibrium coefficient = 1 and LOD score ≥2). Ref-
erences relevant to II, III, and IV are given in the Supplementary Appendix.
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there were no primary or tagging SNPs. For the 
other genes, we identified 270 SNPs in complete 
or near-complete linkage disequilibrium with the 
SNPs that were previously found to be associated 
with coronary artery disease or myocardial infarc-
tion. Although a number of SNPs had a promis-
ing association with coronary artery disease in 
the WTCCC study or with myocardial infarction 
in the German study, only two linked SNPs 
(rs17489268 and rs17411031) tagging the Ser447→
Ter variant in the lipoprotein lipase gene had a 
significant association in both studies (Table 6 in 
the Supplementary Appendix).
Discussion
We jointly analyzed data from two distinct but 
complementary genomewide association studies 
of coronary artery disease and myocardial infarc-
tion that performed ascertainment in similar ways 
and that involved the same genotyping platform. 
Sequential and combined analyses of the two 
data sets allowed us to identify several new genetic 
loci, which individually and in aggregate consid-
erably affect the risk of coronary artery disease.
The association of chromosome 9p21.3 with 
coronary artery disease was the strongest found 
in the WTCCC study.5 The finding that this locus 
was also most strongly associated with myocar-
dial infarction in the German study provides com-
pelling proof of its involvement in coronary artery 
disease. The evidence of association is strong, the 
risk variant is common, and each copy of the 
allele substantially increases the probability of 
the disease. These findings unequivocally dem-
onstrate a major genetic risk variant at this locus.
Indeed, during revision of this manuscript, 
two other genomewide studies reported a strong 
association of the same 9p21.3 locus with coro-
nary artery disease and myocardial infarction,13,14 
making this the most highly replicated locus 
for coronary artery disease identified to date. 
The region contains the coding sequences of 
genes for two cyclin-dependent kinase inhibitors, 
CDKN2A (encoding the prototypic INK4 protein 
p16INK4a) and CDKN2B (encoding p15INK4b), 
which play an important role in the regulation 
of the cell cycle and may be implicated, through 
their role in TGF-β–induced growth inhibition, 
in the pathogenesis of atherosclerosis.15-17 Al-
though regulation of one or both of the CDKN2 
genes may explain the association with coronary 
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artery disease, other explanations also need to 
be considered, including involvement of the meth-
ylthioadenosine phosphorylase (MTAP) gene or 
of other expressed sequences located in the re-
gion. The same region has also recently been 
associated with increased susceptibility to type 2 
diabetes,18-20 raising the possibility of a shared, 
rather than a single, mechanism causing both 
coronary artery disease and diabetes.
The association of chromosome 6q25.1 with 
coronary artery disease maps to the MTHFD1L 
gene, which encodes the mitochondrial isozyme 
of C1-tetrahydrofolate (THF) synthase.21,22 The 
family of C1-THF synthases is used in a variety 
of cellular processes, particularly the synthesis 
of purine and methionine.21 Therefore, MTHFD1L 
activity may also contribute to plasma homocys-
teine levels,21,23 raising the possibility of a link 
between MTHFD1L variants and this risk factor 
for coronary artery disease.24 A preliminary anal-
ysis of data from 1070 persons in the AtheroGene 
study25 has not revealed an association between 
rs6922269 genotypes and plasma homocysteine 
levels (Tiret L, Blankenberg S: personal commu-
nication). Nevertheless, further studies in a wider 
range of subjects are needed to investigate this 
possibility.
Our findings demonstrate the main strength 
of a genomewide approach — namely, the pos-
sibility of identifying hitherto unsuspected loci 
that increase susceptibility to complex diseases. 
However, the mechanisms underlying the newly 
identified associations are often not immedi-
ately obvious. Indeed, the mechanisms for the 
association of signals on chromosomes 9p21.3, 
6q25.1, and 2q36.3 with coronary artery disease 
all require elucidation. Similarly, none of the chro-
mosomal loci identified in the combined analy-
sis have previously been strongly linked to coro-
nary artery disease. However, genes in several of 
the loci (PSRC1 at 1p13.3, MIA3 at 1q41, and 
SMAD3 at 15q22.33) play a role in cell growth or 
inhibition.26-29 These processes are fundamental 
for the formation and progression of atheroscle-
rotic plaque and also for plaque instability.30 Our 
results suggest that genetic regulation of these 
processes plays an important role in the develop-
ment of coronary artery disease and myocardial 
infarction.
Some loci from the WTCCC study that we at-
tempted to replicate did not show association in 
the German study. These negative data under-
score the need to view genomewide associations 
with caution, despite their statistical strength, un-
til they have been replicated in appropriate vali-
dation samples. In this context, caution should 
also be exercised with regard to the four loci 
identified in our combined analysis.31
Our primary objective was to identify loci with 
significant associations with coronary artery dis-
ease independently of any biologic assumptions. 
Nonetheless, the genotyping platform also offered 
an opportunity to examine genetic variants in 
genes with previously reported associations. In-
deed, several showed evidence of an association 
in one of our studies. However, only SNPs in the 
lipoprotein lipase gene had evidence of an asso-
ciation in both studies. This finding is in agree-
ment with those in most recent systematic studies 
that were largely unsuccessful in replicating ini-
tial findings in candidate genes.32 However, many 
of the previously studied gene variants are poorly 
tagged on the GeneChip array, which clearly fails 
to cover the full extent of even common variation 
in these genes.
Whether our findings can be translated into 
better prevention or treatment for coronary artery 
disease will become clear only over time and with 
further research. Although the odds ratios for 
each locus are modest, as anticipated for a poly-
genic disorder, the estimates of population attrib-
utable fractions for the three validated loci are 
substantial, both individually and in aggregate. 
This observation offers the potential for improved 
overall coronary risk prediction. However, the 
case subjects in both studies had a strong fam-
ily history of premature coronary artery disease, 
which might have enhanced the power to detect 
an association with coronary artery disease but 
also might have increased the estimated popula-
tion attributable risks beyond that of sporadic 
cases, and further analysis of the loci in a wider 
range of subjects is necessary. Further studies 
are also needed to investigate the associations of 
the loci with other types of atherosclerotic dis-
ease, as well as with cardiovascular risk factors 
and markers. At a genetic level, studies should 
focus on fine mapping of the associated regions 
and thorough investigation of candidate genes. 
Our results provide a framework for all these ad-
ditional studies.
Our analysis has several important limitations. 
Although the GeneChip array typed over 500,000 
variants, a substantial percentage could not be 
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evaluated, for reasons given in the Supplemen-
tary Appendix. Furthermore, to reduce the effect 
of multiple testing, we used only the rather con-
servative Cochran–Armitage test for trend (an 
additive model) to screen the WTCCC data for 
significant associations. These limitations make 
it likely that some loci were missed and that fur-
ther analysis of the data and subsequent valida-
tion will reveal other loci.
Nonetheless, by using a sequential strategy of 
initial replication and subsequent combination of 
information from the two genomewide associa-
tion studies, we were able to describe several new 
genetic loci for coronary artery disease and myo-
cardial infarction that have a considerable effect 
on the risk of these diseases and that merit in-
depth follow-up studies. Most important, the find-
ing that a single locus was the strongest signal 
in two separate studies carries promise for clini-
cally relevant progress in our understanding of 
the genetics of coronary artery disease. As the 
current activity in genomewide association stud-
ies of complex traits accelerates, our approach 
may also provide a paradigm for combining the 
results of such studies to maximize the amount 
of valuable information that can be extracted 
from these expensive and laborious experiments.
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